Our client:

Founded as a spin-out from the University of Manchester, C4X Discovery (AIM: C4XD) aims to create the world’s most productive drug discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines; their pre-clinical discovery portfolio is focused on inflammation, neurodegeneration, and oncology


The challenge:

C4X’s disruptive model of value required a fresh approach to the valuation of peri-clinical biotech companies, and a CFO with an extremely active presence in the UK and US markets who could create an enthusiasm for progressive models of company valuation. The successful candidate would influence the UK market’s perception of C4X by importing new valuation and business models from the world’s most agile biotech community


How our approach made a difference:

The RSA Group ran an expedited process encompassing interim and retained search, comparative analysis, formal referencing and due diligence, that delivered a new CFO in under six weeks from briefing to start date

Share this: